Skip to main content

Oncolytic Virus Immunotherapy

Let's spread the word about Immunotherapy! Click to share this page with your community.

img_table4_Oncolytic.pngOncolytic virus immununotherapy uses a modified virus that can both cause tumor cells to self destruct and activate a greater immune response
How does it work?

  • Oncolytic viruses are viruses that directly kill (“lyse”) cancer cells and can also activate cells of the immune system, such as dendritic cells and T cells, to target and eliminate cancer throughout the body
  • Sometimes, oncolytic viruses are genetically modified to produce immune-stimulating chemicals, or to make them more specific for cancer cells
  • Oncolytic virus immunotherapies are often combined with other types of cancer immunotherapies, including therapeutic cancer vaccines and mAb therapy

For which cancers is it currently being used or being studied?

  • One oncolytic virus, talimogene laherparepvec, or T-VEC (Imlygic™), is FDA-approved, for the treatment of metastatic melanoma
  • Oncolytic virus immunotherapies are currently being studied in clinical trials for a number of cancers, including:
    • CG0070 (bladder)
    • Reolysin (prostate, colorectal, ovarian, lung, and breast)
    • CAVATAK (melanoma)
    • JX-594 (ovarian)
    • MV-NIS (multiple myeloma)
    • And many more

*Immunotherapy results may vary from patient to patient.